New York, Jan 12, 2026, 11:53 EST — Regular session
Shares of Recursion Pharmaceuticals climbed Monday following the release of an updated investor presentation via a Form 8-K filing. The Nasdaq-traded stock gained 4.4%, reaching $4.87 late morning, putting the company’s market cap near $2.1 billion.
The filing comes as executives and investors gather in San Francisco for the J.P. Morgan Healthcare Conference, a week known for sparking deal talk and shifting outlooks for small biotech firms. “The need to take big swings becomes more pressing,” Jeremy Meilman, JPMorgan’s global co-head of healthcare investment banking, told the Financial Times.
Biotech shares slipped Monday, dragging the SPDR S&P Biotech ETF down roughly 1.6%. Recursion bucked the trend with a notable move.
Recursion reported $755 million in cash, cash equivalents, and restricted cash at the end of 2025 in its January presentation. The company anticipates its cash runway will last through the end of 2027, factoring in risk-adjusted inflows from partnerships. It projects a cash burn for 2026 of under $390 million, calculated as operating cash flow minus capital expenditures and excluding partnership and financing inflows. Key milestones include planned FDA engagement for its lead candidate, REC-4881, in the first half of 2026.
Recursion flagged data for REC-4881 in familial adenomatous polyposis, a hereditary disorder that spurs polyp growth and boosts colon cancer risk. Among 12 evaluable patients at Week 13, the median total polyp burden fell 43%, with 75% hitting the company’s responder criteria. The firm reported 18 treatment-related adverse events, largely Grade 1 or 2, alongside three Grade 3 incidents, no Grade 4 or 5 events, and four patients who discontinued.
Investors are focused on what’s next: dosing, trial design, and the pace at which the program can scale from a small study to one regulators can actually rely on. Conference week tends to amplify every single detail.
The downside is clear. If upcoming data weaken or safety concerns mount, the stock might quickly lose Monday’s gains. A change in risk appetite or any shortfall in expected partnership funding could trigger the same reaction.
Recursion is set to appear in the public-company sessions at 10:30 a.m. Pacific time Tuesday, per the conference agenda. Traders will be watching closely for updates on timelines, FDA strategy, and partnership developments.
Related articles: NASDAQ:RXRX
